Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Stedman

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Gastroenterology|January 18, 2012
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis CTom W Chu, Rohit Kulkarni, Edward J Gane, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 25, 2019
Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject DrugsAmanda J Wade, Joseph S Doyle, Edward Gane, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 13, 2012
Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interactionToshihiko Nishimura, Toshiko Nishimura, Yajing Hu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 30, 2019
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver DiseaseEdward Gane, Fred Poordad, Neddie Zadeikis, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 16, 2023
Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject DrugsQinglu Cheng, Evan B Cunningham, Sophy Shih, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 14, 2019
Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International StudyAndreea A Artenie, Evan B Cunningham, Gregory J Dore, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2020
Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject DrugsEvan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.
The International Journal on Drug Policy|November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapyJason Grebely, Brian Conway, Evan B Cunningham, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Gastroenterology|January 18, 2012
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis CTom W Chu, Rohit Kulkarni, Edward J Gane, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 25, 2019
Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject DrugsAmanda J Wade, Joseph S Doyle, Edward Gane, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 13, 2012
Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interactionToshihiko Nishimura, Toshiko Nishimura, Yajing Hu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 30, 2019
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver DiseaseEdward Gane, Fred Poordad, Neddie Zadeikis, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 16, 2023
Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject DrugsQinglu Cheng, Evan B Cunningham, Sophy Shih, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 14, 2019
Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International StudyAndreea A Artenie, Evan B Cunningham, Gregory J Dore, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2020
Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject DrugsEvan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.
The International Journal on Drug Policy|November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapyJason Grebely, Brian Conway, Evan B Cunningham, et al.
Pageof 2